Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + apatinib + chemotherapy as neoadjuvant treatment for stage IIIA-N2 NSCLC
ChiCTR2200059608Phase 2Completed
- Sponsor
- Fujian Provincial Hospital
- Start
- May 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab and Rivoceranib in non-small cell lung cancer (NSCLC), sponsored by Fujian Provincial Hospital. Primary endpoint: Major pathological response. Started May 2021; status: completed.
02
Drugs
camrelizumabRivoceranib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2200059608.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200059608.